Submitted:
26 November 2024
Posted:
26 November 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Evolving Definitions of Drug Addiction
3. Method
4. Results
Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Gozal, D.; Molfese, D.L. Attention deficit hyperactivity disorder: From genes to patients; Springer Science & Business Media: 2005.
- Rasmussen, N. Chapter Two - Amphetamine-Type Stimulants: The Early History of Their Medical and Non-Medical Uses. In International Review of Neurobiology, Taba, P., Lees, A., Sikk, K., Eds.; Academic Press: 2015; Volume 120, pp. 9-25.
- Ray, H.M. The obese patient; a statistical study and analysis of symptoms, diagnosis and metabolic abnormalities; sex differences; treatment. Am J Dig Dis 1947, 14, 153-162. [CrossRef]
- Bower, E.A.; Phelan, J.R. Use of amphetamines in the military environment. Lancet 2003, 362 Suppl, s18-19. [CrossRef]
- Questions and Comments. BMJ 1955, 1, 679.
- Kiloh, L.G.; Brandon, S. Habituation and addiction to amphetamines. Br Med J 1962, 2, 40-43. [CrossRef]
- Uebel-von Sandersleben, H.; Dangel, O.; Fischer, R.; Ruhmann, M.; Huss, M. Effectiveness and safety of dexamphetamine sulfate (Attentin(®)) in the routine treatment of children and adolescents with ADHD: results from a 12-month non-interventional study. Scand J Child Adolesc Psychiatr Psychol 2021, 9, 73-86. [CrossRef]
- Castells, X.; Blanco-Silvente, L.; Cunill, R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2018, 8, Cd007813. [CrossRef]
- Biederman, J.; Boellner, S.W.; Childress, A.; Lopez, F.A.; Krishnan, S.; Zhang, Y. Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study. Biological Psychiatry 2007, 62, 970-976. [CrossRef]
- Biederman, J.; Wigal, S.B.; Spencer, T.J.; McGough, J.J.; Mays, D.A. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clin Ther 2006, 28, 280-293. [CrossRef]
- Faraone, S.V.; Buitelaar, J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010, 19, 353-364. [CrossRef]
- Daly, B.P.; Creed, T.; Xanthopoulos, M.; Brown, R.T. Psychosocial treatments for children with attention deficit/hyperactivity disorder. Neuropsychol Rev 2007, 17, 73-89. [CrossRef]
- Faraone, S.V.; Buitelaar, J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. European Child & Adolescent Psychiatry 2010, 19, 353-364. [CrossRef]
- James, R.S.; Sharp, W.S.; Bastain, T.M.; Lee, P.P.; Walter, J.M.; Czarnolewski, M.; Castellanos, F.X. Double-Blind, Placebo-Controlled Study of Single-Dose Amphetamine Formulations in ADHD. Journal of the American Academy of Child & Adolescent Psychiatry 2001, 40, 1268-1276. [CrossRef]
- Fredriksen, M.; Halmøy, A.; Faraone, S.V.; Haavik, J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies. European Neuropsychopharmacology 2013, 23, 508-527. [CrossRef]
- Department of Health, P.B.S.D.u.s.-c. Attention Deficit Hyperactivity Disorder: Utilisation Analysis. 2023.
- Briars, L.; Todd, T. A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder. J Pediatr Pharmacol Ther 2016, 21, 192-206. [CrossRef]
- Grimmsmann, T.; Himmel, W. The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany. European Journal of Clinical Pharmacology 2021, 77, 107-115. [CrossRef]
- Renoux, C.; Shin, J.-Y.; Dell'Aniello, S.; Fergusson, E.; Suissa, S. Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. Br J Clin Pharmacol 2016, 82, 858-868. [CrossRef]
- Shearer, J.; Wodak, A.; Mattick, R.P.; Van Beek, I.; Lewis, J.; Hall, W.; Dolan, K. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001, 96, 1289-1296. [CrossRef]
- Longo, M.; Wickes, W.; Smout, M.; Harrison, S.; Cahill, S.; White, J.M. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction 2010, 105, 146-154. [CrossRef]
- Galloway, G.P.; Buscemi, R.; Coyle, J.R.; Flower, K.; Siegrist, J.D.; Fiske, L.A.; Baggott, M.J.; Li, L.; Polcin, D.; Chen, C.Y.; et al. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther 2011, 89, 276-282. [CrossRef]
- Hendricks, E.J. Off-label drugs for weight management. Diabetes Metab Syndr Obes 2017, 10, 223-234. [CrossRef]
- Poulton, A.S.; Hibbert, E.J.; Champion, B.L.; Cook, T.L.; Alais, D.; Coulshed, D.S. Piloting a new approach to the treatment of obesity using dexamphetamine. Frontiers in endocrinology 2015, 6, 14-14. [CrossRef]
- Rasmussen, N. America's first amphetamine epidemic 1929-1971: a quantitative and qualitative retrospective with implications for the present. Am J Public Health 2008, 98, 974-985. [CrossRef]
- Diagnostic and statistical manual of mental disorders, 2d ed.; American Psychiatric Association: Washington, 1968.
- Diagnostic and statistical manual of mental disorders : DSM-3, Third edition. ed.; American Psychiatric Association: Washington, D.C, 1980.
- Broyles, L.M.; Binswanger, I.A.; Jenkins, J.A.; Finnell, D.S.; Faseru, B.; Cavaiola, A.; Pugatch, M.; Gordon, A.J. Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response. Subst Abus 2014, 35, 217-221. [CrossRef]
- O'Brien, C.P.; Volkow, N.; Li, T.K. What's in a word? Addiction versus dependence in DSM-V. Am J Psychiatry 2006, 163, 764-765. [CrossRef]
- Diagnostic and statistical manual of mental disorders : DSM-5; American Psychiatric Association: Arlington, VA, 2013.
- Diagnostic and statistical manual of mental disorders, 4th ed; American Psychiatric Publishing, Inc.: Arlington, VA, US, 1994; pp. xxvii, 886-xxvii, 886.
- Organization, W.H. International Classification of Diseases, Eleventh Revision (ICD-11), World Health Organization (WHO) 2019/2021. 2019.
- Sussman, S.; Sussman, A.N. Considering the definition of addiction. Int J Environ Res Public Health 2011, 8, 4025-4038. [CrossRef]
- Oswald, I.; Thacore, V.R. AMPHETAMINE AND PHENMETRAZINE ADDICTION. PHYSIOLOGICAL ABNORMALITIES IN THE ABSTINENCE SYNDROME. Br Med J 1963, 2, 427-431. [CrossRef]
- Shekelle PG, M.M., Luoto J, et al. Global Health Evidence Evaluation Framework [Internet]. Table B.9, NHMRC Evidence Hierarchy: designations of ‘levels of evidence’ according to type of research question (including explanatory notes). 2013.
- Carpentier, P.J.; Levin, F.R. Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us? Harvard Review of Psychiatry 2017, 25, 50-64. [CrossRef]
- Morrow, S.A.; Smerbeck, A.; Patrick, K.; Cookfair, D.; Weinstock-Guttman, B.; Benedict, R.H. Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. J Neurol 2013, 260, 489-497. [CrossRef]
- Sorbera, L.A.; Serradell, N.; Rosa, E.; Bolós, J. Lisdexamfetamine mesilate. Treatment of attention deficit hyperactivity disorder. Drugs of the Future 2007, 32, 223-227. [CrossRef]
- Grahn, H.V. Amphetamine addiction and habituation. American practitioner (Philadelphia, Pa 1958, 1962). 9(3), 387-389.
- Bell, D.S.; Trethowan, W.H. Amphetamine addiction. Journal of Nervous and Mental Disease 1961, 133(6), 489-496.
- Kiloh, L.G.; Brandon, S. Habituation And Addiction To Amphetamines. The British Medical Journal 1962, 2, 40-43.
- EXPERT committee on addiction-producing drugs; seventh report. World Health Organ Tech Rep Ser 1957, 1-15.
- Griffith, J.D.; Cavanaugh, J.; Held, J.; Oates, J.A. Dextroamphetamine. Evaluation of psychomimetic properties in man. Arch Gen Psychiatry 1972, 26, 97-100. [CrossRef]
- Dackis, C.A.; Gold, M.S. Addictiveness of central stimulants. Adv Alcohol Subst Abuse 1990, 9, 9-26. [CrossRef]
- Substance Abuse and Mental Health Services Administration. (2006). Results from the 2005 National Survey on Drug Use and Health: National Findings (Office of Applied Studies. 2005.
- Brandon, S.; Smith, D. Amphetamines in general practice. J Coll Gen Pract 1962, 5, 603-606.
- Wilson, C.; Beacon, S. An investigation into the habituating properties of an amphetamine-barbiturate mixture. British Journal of Addiction to Alcohol & Other Drugs 1964, 60, 81-92.
- Clemow, D.B.; Walker, D.J. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med 2014, 126, 64-81. [CrossRef]
- Wilens, T.E.; Adler, L.A.; Adams, J.; Sgambati, S.; Rotrosen, J.; Sawtelle, R.; Utzinger, L.; Fusillo, S. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008, 47, 21-31. [CrossRef]
- Weiss, M.; Hechtman, L. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 2006, 67, 611-619.
- Taylor, F.B.; Russo, J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2001, 21, 223-228. [CrossRef]
- Taylor, F.B.; Russo, J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000, 10, 311-320. [CrossRef]
- Paterson, R.; Douglas, C.; Hallmayer, J.; Hagan, M.; Krupenia, Z. A Randomised, Double-Blind, Placebo-Controlled Trial of Dexamphetamine in Adults with Attention Deficit Hyperactivity Disorder. Australian & New Zealand Journal of Psychiatry 1999, 33, 494-502. [CrossRef]

| 1 | Engagement in behavior that can become addictive (for example: abuse of an illicit substance) |
| 2 | Preoccupation with the behavior including planning, engaging, and recovering from its desired effects |
| 3 | Temporary satiation |
| 4 | Loss of control |
| 5 | Suffering negative consequences |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).